[PSA follow-up after radical prostatectomy].
Explore the source record for details and available documents.
Biomarkers, Tumor↗
Biomedical subjects
Shiro Baba
Publications and source records attributed to Shiro Baba.
Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
BACKGROUND: The matrix metalloproteinases (MMP)-2 and MMP-9 are known to degrade the extra-cellular matrix (ECM) and to be involved in the invasion and metastasis of cancer cells. In order to establish the clinical significance of the determination of serum MMP-2 levels for prostate cancer (PCa), we determined serum levels of MMP-2 and PSA in patients with PCa at different stages. PATIENTS AND METHODS: In this study, serum samples from 39 patients with prostate hypertrophy and 51 PCa patients diagnosed at Kitasato University Hospital, Japan, were examined. MMP-2 levels were determined by measuring pro-MMP-2 using an enzyme immunoassay. PSA was also determined by enzyme immunoassay. Immunohistochemical analysis of prostate cancer specimens was performed according to the labeled streptavidin-biotinylated antibody (LSAB) method. RESULTS: Serum levels of MMP-2 and PSA increased with PCa disease progression. Serum levels of both markers in patients with invasive and metastatic PCa were significantly higher than in those with localized PCa. No significant association was found between serum levels of MMP-2 and PSA in patients with PCa. Extremely high levels of MMP-2 greater than 950 ng/ml or increased levels of PSA over 300 ng/ml were found only in PCa patients with bone metastases. CONCLUSION: Our findings indicate that MMP-2 may be involved in the invasion and metastasis of PCa and that serum MMP-2 levels may be able to become an auxiliary indicator of serum PSA to detect the progression of PCa.
Aged↗
Changes in serum IgG oligosaccharide chains with prostate cancer progression.
BACKGROUND: Changes of serum IgG oligosaccharide chain structure have been found in B cell lineage tumors and autoimmune diseases. Currently, the cancer-associated carbohydrate epitopes CA72-4 and CA15-3 are used as serum tumor markers. In the present study, we analyzed the structure of serum IgG oligosaccharide chains in prostate cancer (PCa) patients using the simple new method of fluorophore-associated carbohydrate electrophoresis (FACE). We also evaluated the relationship between changes of serum IgG oligosaccharide chain structure and serum concentration of prostate-specific antigen (PSA). MATERIALS AND METHODS: The structure of serum IgG oligosaccharide chains from 12 PCa patients (6 localized cancer, 6 metastatic cancer) and 10 healthy controls was evaluated by FACE. PSA levels in serum were determined by enzyme immunoassay. RESULTS: Fr 1 (monogalactosyl oligosaccharide) and Fr 2 (digalactosyl oligosaccharide) decreased significantly (p<0.05), while Fr 4 (agalactosyl IgG oligosaccharide) increased with PCa tumorprogression. The Fr 4/Fr 1+2 ratio in metastatic PCa patients was significantly higher than in healthy controls (p<0.05), and there was a significant correlation (r=0.84, p<0.05) between serum PSA levels and the Fr 4/Fr 1+2 ratio in all patients with PCa. CONCLUSION: The changes of serum IgG oligosaccharide chain structure with PCa progression are based on the abnormality of glycosylation in PCa metastasis. Therefore, the analysis of serum IgG oligosaccharide chain structure by FACE may be an auxiliary indicator of PSA for monitoring PCa progression.
Aged↗